Literature DB >> 15702859

Survival of the probiotic, L. plantarum 299v and its effects on the faecal bacterial flora, with and without gastric acid inhibition.

D Goossens1, D Jonkers, M Russel, A Thijs, A van den Bogaard, E Stobberingh, R Stockbrügger.   

Abstract

INTRODUCTION: Probiotic bacteria have to survive passage through the gastrointestinal tract. In this placebo-controlled double-blind study, the effect of Lactobacillus plantarum 299v on the faecal flora was studied with and without gastric acid inhibition.
METHODS: Thirty-two healthy volunteers were given pantoprazole (40 mg/day) or placebo for 3 weeks from week 2 until week 4. In addition, from week 3 until week 4, L. plantarum 299v in an oatmeal-fermented drink (10(9) CFU/ml) was given twice daily to both groups. From each healthy volunteer, faecal samples were collected at the end of week 1, 2, 4 and 8 (4 weeks after cessation of L. plantarum 299v and pantoprazole/placebo). Several aerobically and anaerobically growing bacteria were counted and short chain fatty acid concentrations were determined.
RESULTS: In both the pantoprazole and the placebo group, median lactobacilli counts increased significantly in week 4 compared to week 1 (from log 4.5 to 8.0 CFU/g faeces in pantoprazole and from log 4.2 to 7.7 CFU/g faeces in placebo group) and decreased significantly in week 8 (to log 4.5 CFU/g faeces in pantoprazole and log 4.3 CFU/g faeces in placebo group). These lactobacilli were identified as L. plantarum 299v. No significant differences were observed in all other bacterial counts and short chain fatty acid concentrations.
CONCLUSIONS: The comparable increase of faecal lactobacilli counts in both the pantoprazole and the placebo-treated group demonstrates that L. plantarum 299v survives passage through the gastrointestinal tract irrespective of gastric acidity. The increment of the intra-gastric pH in combination with L. plantarum 299v did not modulate bacterial composition and/or the production of short chain fatty acids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15702859     DOI: 10.1016/j.dld.2004.07.018

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  7 in total

1.  Probiotics are sensitive microorganisms: Lactobacillus can be affected by stomach acid, antibiotic, and bowel cleansing.

Authors:  Hakan Alagozlu; Tarkan Karakan
Journal:  Dig Dis Sci       Date:  2012-07-18       Impact factor: 3.199

2.  Oral administration of live exopolysaccharide-producing Pediococcus parvulus, but not purified exopolysaccharide, suppressed Enterobacteriaceae without affecting bacterial diversity in ceca of mice.

Authors:  Cecilia Lindström; Jie Xu; Rickard Oste; Olle Holst; Göran Molin
Journal:  Appl Environ Microbiol       Date:  2013-06-14       Impact factor: 4.792

Review 3.  Perspectives from the Society for Pediatric Research: Probiotic use in urinary tract infections, atopic dermatitis, and antibiotic-associated diarrhea: an overview.

Authors:  Catherine S Forster; Michael H Hsieh; Michael D Cabana
Journal:  Pediatr Res       Date:  2020-12-07       Impact factor: 3.756

4.  Probiotic strain Lactobacillus plantarum 299v increases iron absorption from an iron-supplemented fruit drink: a double-isotope cross-over single-blind study in women of reproductive age.

Authors:  Michael Hoppe; Gunilla Önning; Anna Berggren; Lena Hulthén
Journal:  Br J Nutr       Date:  2015-10-28       Impact factor: 3.718

Review 5.  Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review.

Authors:  Lynne V McFarland
Journal:  BMJ Open       Date:  2014-08-25       Impact factor: 2.692

6.  Freeze-dried Lactobacillus plantarum 299v increases iron absorption in young females-Double isotope sequential single-blind studies in menstruating women.

Authors:  Michael Hoppe; Gunilla Önning; Lena Hulthén
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

7.  Study protocol for the safety and efficacy of probiotic therapy on days alive and out of hospital in adult ICU patients: the multicentre, randomised, placebo-controlled Restoration Of gut microflora in Critical Illness Trial (ROCIT).

Authors:  Edward Litton; Matthew Anstey; David Broadhurst; Andy R Chapman; Andrew Currie; Janet Ferrier; Joel Gummer; Alisa Higgins; Jolene Lim; Laurens Manning; Erina Myers; Katrina Orr; Anne-Marie Palermo; Andrew Paparini; Susan Pellicano; Edward Raby; Anu Rammohan; Adrian Regli; Bernhard Richter; Sam Salman; Tobias Strunk; Sharon Waterson; Brad Wibrow; Fiona M Wood
Journal:  BMJ Open       Date:  2020-06-21       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.